Familial hypercholesterolaemia (FH) is an autosomal dominant hyperlipidaemia disorder. Untreated FH results in premature coronary artery disease (typically fourth decade in men, up to ten years later in women).
Clinical management, involving statin therapy, is usually provided through specialist lipid clinics. FH is underdiagnosed, with an estimated prevalence in the UK of 1 in 500.
Serum cholesterol concentrations are elevated from birth and are usually at least double the normal values. Premature coronary artery disease is a key feature: >50% risk in men by age 50; at least 30% risk in women by age 60.
Tendon xanthomata (virtually diagnostic); premature corneal arcus and xanthelasmas may also be present.
FH is an autosomal dominant condition, which means that each child of someone with FH has a 50%, or 1 in 2, chance of inheriting the gene alteration that causes the condition.
As FH is common, sometimes both parents can have the condition. In this case each child has a:
50% chance of inheriting the gene alteration from only one parent, resulting in the usual form of FH.
25% chance of inheriting the gene alteration from both parents. This is called homozygous FH and is a more severe life-threatening condition with the risk of coronary heart disease in childhood.
25% chance of not having FH, as they have not inherited the gene alteration from either parent.
FH results from a gene alteration in one of three genes: LDLR; APOB and PCSK9.
Alterations in the LDLR gene account for 80%-95% of cases, with over 200 different gene alterations documented in the UK. Alterations in the APOB gene and PCSK9 gene occur in 5% and 2% of UK patients respectively.